435 related articles for article (PubMed ID: 29428298)
41. Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung.
Martini SV; Silva AL; Ferreira D; Rabelo R; Ornellas FM; Gomes K; Rocco PR; Petrs-Silva H; Morales MM
Cell Physiol Biochem; 2016; 39(2):544-53. PubMed ID: 27384068
[TBL] [Abstract][Full Text] [Related]
42. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene.
Halbert CL; Allen JM; Miller AD
Nat Biotechnol; 2002 Jul; 20(7):697-701. PubMed ID: 12089554
[TBL] [Abstract][Full Text] [Related]
43. Positron Emission Tomography Quantitative Assessment of Off-Target Whole-Body Biodistribution of I-124-Labeled Adeno-Associated Virus Capsids Administered to Cerebral Spinal Fluid.
Rosenberg JB; Fung EK; Dyke JP; De BP; Lou H; Kelly JM; Reejhsinghani L; Ricart Arbona RJ; Sondhi D; Kaminsky SM; Cartier N; Hinderer C; Hordeaux J; Wilson JM; Ballon DJ; Crystal RG
Hum Gene Ther; 2023 Nov; 34(21-22):1095-1106. PubMed ID: 37624734
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
[TBL] [Abstract][Full Text] [Related]
45. CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain.
Mathiesen SN; Lock JL; Schoderboeck L; Abraham WC; Hughes SM
Mol Ther Methods Clin Dev; 2020 Dec; 19():447-458. PubMed ID: 33294493
[TBL] [Abstract][Full Text] [Related]
46. Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys.
Hordeaux J; Hinderer C; Buza EL; Louboutin JP; Jahan T; Bell P; Chichester JA; Tarantal AF; Wilson JM
Hum Gene Ther; 2019 Aug; 30(8):957-966. PubMed ID: 31017018
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
48. Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.
Powell SK; Khan N; Parker CL; Samulski RJ; Matsushima G; Gray SJ; McCown TJ
Gene Ther; 2016 Nov; 23(11):807-814. PubMed ID: 27628693
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.
Grimm D; Lee JS; Wang L; Desai T; Akache B; Storm TA; Kay MA
J Virol; 2008 Jun; 82(12):5887-911. PubMed ID: 18400866
[TBL] [Abstract][Full Text] [Related]
50. Tissue and cell-type-specific transduction using rAAV vectors in lung diseases.
Kochergin-Nikitsky K; Belova L; Lavrov A; Smirnikhina S
J Mol Med (Berl); 2021 Aug; 99(8):1057-1071. PubMed ID: 34021360
[TBL] [Abstract][Full Text] [Related]
51. Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice.
Wu J; Solanes P; Nist-Lund C; Spataro S; Shubina-Oleinik O; Marcovich I; Goldberg H; Schneider BL; Holt JR
Mol Ther; 2021 Mar; 29(3):973-988. PubMed ID: 33212302
[TBL] [Abstract][Full Text] [Related]
52. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism.
Mulcrone PL; Lam AK; Frabutt D; Zhang J; Chrzanowski M; Herzog RW; Xiao W
Sci Rep; 2023 May; 13(1):8436. PubMed ID: 37231038
[TBL] [Abstract][Full Text] [Related]
53. AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo.
Powell SK; Samulski RJ; McCown TJ
Mol Ther; 2020 May; 28(5):1373-1380. PubMed ID: 32213322
[TBL] [Abstract][Full Text] [Related]
54. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.
Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL
Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800
[TBL] [Abstract][Full Text] [Related]
55. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
Yang L; Li J; Xiao X
Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
[TBL] [Abstract][Full Text] [Related]
56. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants.
Weinmann J; Weis S; Sippel J; Tulalamba W; Remes A; El Andari J; Herrmann AK; Pham QH; Borowski C; Hille S; Schönberger T; Frey N; Lenter M; VandenDriessche T; Müller OJ; Chuah MK; Lamla T; Grimm D
Nat Commun; 2020 Oct; 11(1):5432. PubMed ID: 33116134
[TBL] [Abstract][Full Text] [Related]
57. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.
Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM
Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388
[TBL] [Abstract][Full Text] [Related]
58. AAV Vectors for Efficient Gene Delivery to Rodent Hearts.
Lopez-Gordo E; Kohlbrenner E; Katz MG; Weber T
Methods Mol Biol; 2019; 1950():311-332. PubMed ID: 30783983
[TBL] [Abstract][Full Text] [Related]
59. Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.
Reid CA; Ertel KJ; Lipinski DM
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6429-6439. PubMed ID: 29260200
[TBL] [Abstract][Full Text] [Related]
60. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS.
Stanton AC; Lagerborg KA; Tellez L; Krunnfusz A; King EM; Ye S; Solomon IH; Tabebordbar M; Sabeti PC
Med; 2023 Jan; 4(1):31-50.e8. PubMed ID: 36417917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
